

---

## HL7-Standards zur medizinischen Wissensverarbeitung: Arden-Syntax und ArdenML

|  |   |
|--|---|
| <p><b><i>Stefan Sabutsch</i></b></p> <p><b>ELGA GmbH und<br/>Präsident von HL7 Austria</b></p> | <p><b><i>Klaus-Peter Adlassnig</i></b></p> <p><b>Medizinische Universität Wien und<br/>Medexter Healthcare GmbH</b></p> |
| <p><b><i>Karsten Fehre</i></b></p> <p><b>Medexter Healthcare GmbH</b></p>                      | <p><b><i>Michael Binder</i></b></p> <p><b>Medizinische Universität Wien</b></p>   |

Workshop, eHealth 2014, Wien, 22. Mai 2014

---

---

## **Inhalt**

- Begrüßung (Sabutsch)
  - HL7 und Standards (Sabutsch)
  - Klinische Entscheidungsunterstützung (Adlassnig)
  - Arden-Syntax und ArdenML (Fehre)
  - Anwendungen (Adlassnig)
  - Klinische Perspektiven (Binder)
  - Verantwortung und Medizinprodukt (Adlassnig)
-

---

## HL7 – global interoperability standards



- HL7 provides standards for interoperability
    - improve care delivery, optimize workflow, reduce ambiguity and enhance knowledge transfer
  - HL7 Standards
    - Version 2.x messaging standard
    - Version 3: specifications based on HL7's Reference Information Model (RIM)
      - for messaging and documents
    - CDA® (Clinical Document Architecture): a V3 based document markup standard that specifies the structure and semantics of "clinical documents" → CDA implementation guides
    - Vocabulary Standards
    - CTS2 (Common Terminology Services) – services for accessing and managing terminological content
    - ARDEN Syntax
    - ...
  - HL7 Base Standards are licensed – but that license is free (“license at no cost”)
-

---

## About HL7



- **Health Level Seven International (HL7)**, founded in 1987
  - a not-for-profit, ANSI-accredited standards developing organization in healthcare-IT
  - collaborates with other SDO like ISO, DICOM, IHTSDO, IHE, ...
  - headquarter: USA (Ann Arbor, MI)
  - >2.300 members (healthcare providers, government agencies, vendor community, ...)
  - 34 affiliate organizations around the world (18 in Europe)
- **HL7 Austria**
  - Founded in 2007
  - Activities: information source, support, ballots (eg. CDA IG), e-Learning, courses, meetings/conferences, "Austrian interoperability forum"
  - [www.hl7.at](http://www.hl7.at) Twitter [https://twitter.com/HL7\\_Austria](https://twitter.com/HL7_Austria)



---

## ELGA & Decision Support



- ELGA has (momentary) no decision support mechanisms, but...
  - ELGA gives access to a collection of relevant and highly structured and semantic interoperable healthcare documents (HL7 CDA Rel. 2)
  - ELGA provides supplemental standardized information for a patient  
→ Local EHR can be completed with downloaded information from ELGA
  - The aggregated data pool (local EHR+ELGA) may be used for clinical decision support!
    - Example: ELGA medications, discharge diagnoses, lab results, ...
-

---

## **HL7 activities toward clinical decision support standards**

- **Arden Syntax for Medical Logic Systems**, Version 2.10 (May, 2014)
- HL7 Version 3 Standard: GELLO; A Common Expression Language, Release 2 (April 2010)
- HL7 Version 3 Standard: Virtual Medical Record for Clinical Decision Support (vMR-CDS) Logical Model, Release 2 (January 2014)
- HL7 Version 3 Standard: Clinical Decision Support Knowledge Artifact Specification, Release 1.1 (April 2014)
- ...

<http://www.hl7.org/implement/standards/index.cfm?ref=nav>

---

---

## Arden Syntax and Health Level Seven (HL7)

- A standard language for writing situation-action rules that can trigger alerts based on abnormal clinical events detected by a clinical information system.
  - Each module, referred to as a **medical logic module (MLM)**, contains sufficient knowledge to make a single decision.
    - extended by **packages of MLMs** for complex clinical decision support
  - The Health Level Seven Arden Syntax for Medical Logic Systems, **Version 2.9—including fuzzy methodologies**—was approved by the American National Standards Institute (ANSI) and by Health Level Seven International (HL7) on 14 March 2013
  - **Version 2.10—including ArdenML, an XML-based representation of Arden Syntax MLMs**—was approved on 6 May 2014
    - continuous development since 1989
-

## General MLM Layout

### Maintenance Category

## Library Category

### Knowledge Category

### Resources Category

## Identify an MLM

## Data Types

## Basic Operators

## Curly Braces

## List Operators

## Logical Operators

## Comparison Operators

## String Operators

## Arithmetic Operators

## Other Operators

## Control Statements

## Call/Write Statements and Trigger

```

maintenance
  title: body mass index;
  resourceName: BMI;
  authors: [clemens.f.];
  version: 1.0;
  description:
    calculates body mass index
  calculation:
    bmi = (weight / (height ** 2)) * 723
  keywords:
    bmi, body mass index,
    calculation
  published:
    date: 2009-09-09;
    validation: julius;
  library:
    purpose: body mass index;
    explanation:
      calculation of body mass index
      input: compound list with:
        (bmiRate) rate in kg/
        (bmiWeight) weight in kg
        (bmi) bmi data
      output:
        If the age is not less than 19 then classification is "normal".
        wr. WHO is not normal, a message containing
        the BMI, and the classification will be sent.
  test:
    keywords: BMI, body mass index;
    challenge: 1;
    url: http://www.wikipedia.org/wiki/body_mass_index;
    knowledge:
      type: data_driver;
      data:
        |Original code which passed in parents
        |Age, weight, bmi, = argument;

        |==== DUMMY CODE =====
        |Running values to test GELLO interface - real code would reference YMR
        |bmi = READ ("Factory PQ1185, bmi");
        |weight = READ ("Factory PQ101, wt");
        |bmi = READ ("Factory T5211909101");

        |==== REAL LIFE CODE =====
        |A Statement combination probably for our use cases
        |1. defines an interface which is called to get the birthday of a person
        |LET get-birth-BE INTERFACE ("patient data-MUM");
        |This is what YMR code would look like

        |2. assume the patient ID is passed to the MUM
        |LET patientID-BE argument;

        |3. use the interface to get the patient patient ID
        |LET birth-BE CO ...

        |====
        |priority: 1;
        |enrich: 1;
        |tags:
          | calculation of BMI
          | let bmi be weight / (size ** 2); // BMI
          | calculation of AGE
          | age = current-time - birth; // AGE

        |====
        | classification
        | if the age is less than 19 years then classification = "null"; // BMI for people under 19 not defined
        | else if the bmi is less than 18.5 then classification = "Underweight";
        | else if the bmi is less than 25 then classification = "normal"; // BMI normal range
        | else if the bmi == 25 then let the classification be "Overweight";
        | else
        | bmi = bmi formatted with "%, 0f"; // formatted output
        | conclude classification is present;

        |====
        | return
        | write "The patient's BMI (" bmi ") is not in the normal range and is classified as (" classification ")"; // write result
        | return bmi;

        |====
        | signature: 1;
        | resources:
          | default: de;
          | language: en
          | "arg: "Condition, the patient has the following allergy is pericillin documented.";
          | "label: "The patient's BMI is calculated as follows: (bmi)";
          | "description: "The body mass index (BMI) is a measure of body fat based on a person's mass and height";
          | language: de
          | "arg: "Vermittelt zu, dass ein Patient eine Allergie gegen Penicillin hat.";
          | "label: "Die berechnete Körper-Masse-Index des Patienten beträgt (bmi).";
          | "description: "Der Body-Mass-Index (BMI) ist ein Maß für den Fettgehalt eines Menschen, basierend auf der Masse und der Körpergröße";
    end
  end
end

```



---

## Sample MLM (excerpt)

```
logic:
  result := new bmiResult; // create an empty result object

  weight := latest of weights; // get the latest weight from the list

  size := call mlmForReadSize with patientID; // get the size of the patient calculated by another MLM

  result.bmi := weight / (size ** 2); // calculation of BMI
  age := currenttime - birth; // calculation of AGE

  // classification - the classification is only valid for patients older than 19
  if the age is less than 19 years then result.classification := null;
  elseif the result.bmi is less than 18.5 then result.classification := localized 'under';
  elseif the result.bmi is less than 25 then result.classification := null;
  else let the result.classification be localized 'over';
  endif;

  result.bmi := result.bmi formatted with localized 'msg'; // construct the localized message

  if (time of weight) is before (currenttime - 6 months) then
    conclude false; //no bmi calculation if the latest measure was 6 months ago
  else
    conclude result.classification is present ; // if there is a classification, execute the action slot
  endif;

;;
```

---

---

## **ArdenML: Objectives and applications**

- Provide a complete XML schema for Version 2.10 of the Arden Syntax to express MLMs in XML
  - Thus, Arden Syntax is now compatible with all other HL7 standards based on XML (HL7 version 3, VmR, and others)
  - Further benefit: To be able to use available XML tools
-

---


## ArdenML: Example

```
<Library>
  <Purpose>Test</Purpose>
  <Explanation></Explanation>
  <Keywords></Keywords>
</Library>
<Knowledge>
  <Type>data_driven</Type>
  <Data></Data>
  <Evoke></Evoke>
  <Logic>
    <Assignment>
      <Identifier var='var1' />
      <Assigned>
        <Value otype='time'>1990-03-15T15:00:00</Value>
      </Assigned>
    </Assignment>
    <Assignment>
      <Identifier var='res1' />
      <Assigned>
        <ReplaceYearWith>
          <Identifier var='var1' />
          <Value otype='number'>2011</Value>
        </ReplaceYearWith>
      </Assigned>
    </Assignment>
    <Assignment>
      <Identifier var='res2' />
      <Assigned>
        <ReplaceYearWith>
          <Identifier var='var1' />
          <List>
            <Value otype='number'>2011</Value>
            <Value otype='number'>2010</Value>
          </List>
        </ReplaceYearWith>
      </Assigned>
    </Assignment>
  </Logic>
</Knowledge>
```

---

---

## Cross compilation/transformation of Arden Syntax to/from ArdenML



Team effort by Intermountain Hospital, Salt Lake City, Utah, U.S.A., and Medexter Healthcare, Vienna, Austria

---

---

## Computers in clinical medicine—steps of natural progression

- step 1: patient administration
    - admission, transfer, discharge, and billing
  - step 2: documentation of patients' medical data
    - electronic health record: all media, distributed, life-long (partially fulfilled)
  - **step 3: patient and hospital analytics**
    - data warehouses, quality measures, reporting and research databases, patient recruitment
      - ... population-specific
  - **step 4: clinical decision support**
    - safety net, quality assurance, evidence-based
      - ... patient-specific
-

---

## History

- Clay tablets with cuneiform writing from New Babylonian (about 650 B.C.)
    - instructions to medical examination, diagnosis, and prognosis
  - “Reasoning Foundations of Medical Diagnosis” by Ledley and Lusted in Science (1959)
    - computer-assisted medical diagnosis and therapy
  - medical expert system MYCIN by Shortliffe et al. (Stanford University, 1975)
    - diagnostic and therapeutic proposals for patients suffering from infectious diseases (evaluation JAMA, 1979)
-

# Antimicrobial Selection by a Computer

## A Blinded Evaluation by Infectious Diseases Experts

Victor L. Yu, MD; Lawrence M. Fagan; Sharon M. Wraith; William J. Clancey; A. Carlisle Scott, MS; John Hannigan, MS; Robert L. Blum, MD; Bruce G. Buchanan, PhD; Stanley N. Cohen, MD

● An evaluation of a computer-based consultation system called MYCIN was made. Eight independent evaluators with special expertise in the management of meningitis compared MYCIN's choice of antimicrobials with the choices of nine human prescribers for ten test cases of meningitis. MYCIN received an acceptability rating of 65% by the evaluators; the corresponding ratings for acceptability of the regimen prescribed by the five faculty specialists ranged from 42.5% to 62.5%. The system never failed to cover a treatable pathogen while demonstrating efficiency in minimizing the number of antimicrobials prescribed. The study design may be useful in assessing the performance of other computer-based clinical decision-making systems.

(JAMA 242:1279-1282, 1979)

DURING the last two decades, many computer programs have been developed to assist physicians in the diagnosis or treatment of a variety of medical disorders.<sup>1</sup> However, to our knowledge, the medical accuracy of these programs has not undergone clinical evaluation by independent experts. We present a comparison of

meningitis before the causative agent had been identified.

The computer program, MYCIN, provides advice for the diagnosis of diseases and the treatment of patients with infectious diseases.<sup>2,3</sup> During the last five years, MYCIN's extensive knowledge base and its therapy-selection process have been

therapy, MYCIN takes into account the specific clinical situations (eg, trauma, neurosurgery), host factors (eg, age, immunosuppression), and the possible presence of unusual pathogens (eg, *Francisella tularensis*, *Candida non-albicans*). In selecting antimicrobial therapy, the system considers antimicrobial factors (eg, organism susceptibility, synergistic combinations) and relative contraindications (eg, patient allergies, poor response to prior therapy).

When knowledge about a new area of infectious disease is incorporated into MYCIN's knowledge base, the system's performance is evaluated to determine whether its therapeutic regimens are as reliable as the regimens that an infectious diseases specialist would recommend. An evaluation of the system's ability to diagnose and treat patients with bacter-

---

## Artificial Intelligence (AI)—applicable to clinical medicine

- *Definition:* AI is the science of artificial simulation of human thought processes with computers.

from: Feigenbaum, E.A. & Feldman, J. (eds.) (1995) *Computers & Thought*. AAAI Press, Menlo Park, back cover.

- It is the **decomposition** of an **entire clinical thought process** and its separate artificial simulation—also of simple instances of “clinical thought”—that make the task of **AI in clinical medicine** manageable.
- A functionally-driven science of AI that **extends clinicians through computer systems** step by step can immediately be established.




artificial-intelligence-augmented clinical medicine

---



# Medical information and knowledge-based systems



---

## Clinical decision support and quality assurance

patients' structured medical data




|  |  |
|--|--|
| <p><b>diagnostic support</b></p> <ul style="list-style-type: none"><li>• clinical alerts, reminders, calculations</li><li>• data interpretation, (tele)monitoring</li><li>• differential diagnostic consultation<ul style="list-style-type: none"><li>– rare diseases, rare syndromes</li><li>– further or redundant investigations</li><li>– pathological signs accounted for</li></ul></li><li>• consensus-criteria-based evaluation<ul style="list-style-type: none"><li>– definitions, classification criteria</li></ul></li></ul> | <p><b>therapy advice</b></p> <ul style="list-style-type: none"><li>• drug alerts, reminders, calculations<ul style="list-style-type: none"><li>– indication, contraindications, redundant medications, substitutions</li><li>– adverse drug events, interactions, dosage calculations, consequent orders</li></ul></li><li>• management of antimicrobial therapies, resistance</li><li>• (open-loop) control systems</li></ul> |
| <p><b>prognostic prediction</b></p> <ul style="list-style-type: none"><li>• illness severity scores, prediction rules</li><li>• trend detection and visualization</li></ul>  | <p><b>patient management guidelines &amp; quality assurance</b></p> <ul style="list-style-type: none"><li>• evidence-based reminders and processes</li><li>• computerized clinical guidelines, protocols, SOPs</li><li>• healthcare-associated infection surveillance</li></ul>  |



highly-structured medical knowledge

---



- studies in Colorado and Utah and in New York (1997)
  - errors in the delivery of health care leading to the death of as many as 98,000 US citizens annually
- causes of errors
  - error or delay in diagnosis
  - failure to order indicated tests
  - use of **errors** indicated tests or therapy
  - failure to act on results of testing or monitoring
  - error in the performance of a test, procedure, or operation
  - error in administering the treatment
  - error in the dose or method of using a drug
  - avoidable delay in treatment or in responding to test
  - failure to provide (indicated) care
  - failure of communication
  - equipment failure
- prevention of errors
  - we must systematically design safety into processes of care

# Perspectives on Informatics

AMIA Board White Paper ■

## Core Content for the Subspecialty of Clinical Informatics

REED M. GARDNER, PHD, J. MARC OVERHAGE, MD, PHD, ELAINE B. STEEN, MA.,  
BENSON S. MUNGER, PHD, JOHN H. HOLMES, PHD, JEFFREY J. WILLIAMSON, DON E. DETMER, MD, MA,  
FOR THE AMIA BOARD OF DIRECTORS

**Abstract** The Core Content for Clinical Informatics defines the boundaries of the discipline and informs the Program Requirements for Fellowship Education in Clinical Informatics. The Core Content includes four major categories: fundamentals, clinical decision making and care process improvement, health information systems, and leadership and management of change. The AMIA Board of Directors approved the Core Content for Clinical Informatics in November 2008.

■ J Am Med Inform Assoc. 2009;16:153–157. DOI 10.1197/jamia.M3045.

### Background

The Core Content for a medical subspecialty defines the boundaries of the discipline and informs the Program Requirements for Fellowship Education. Program Requirements identify the knowledge and skills that must be mastered through the course of fellowship training and specify accreditation requirements for training programs.<sup>1</sup> The American Board of Medical Specialties considers these two documents along with other requirements and factors when deciding whether to establish a new medical subspecialty. The Core Content for Clinical Informatics is the result of a two-year national development process initiated by the American Medical Informatics Association and supported

by the Robert Wood Johnson Foundation.<sup>2</sup> In November 2008, the AMIA Board of Directors approved both the Core Content and Program Requirements for clinical informatics.

### Definition and Description of the Subspecialty

Clinical informaticians transform health care by analyzing, designing, implementing, and evaluating information and communication systems that enhance individual and population health outcomes, improve patient care, and strengthen the clinician-patient relationship.

Clinical informaticians use their knowledge of patient care combined with their understanding of informatics concepts, methods, and tools to:

- assess information and knowledge needs of health care professionals and patients,
- characterize, evaluate, and refine clinical processes,
- develop, implement, and refine clinical decision support systems, and
- lead or participate in the procurement, customization, development, implementation, management, evaluation, and continuous improvement of clinical information systems.

Physicians who are board-certified in clinical informatics collaborate with other health care and information technology professionals to promote patient care that is safe, efficient, effective, timely, patient-centered, and equitable.

As illustrated in Figure 1, clinical informatics encompasses three spheres of activity:

- clinical care (i.e., the provision of clinical services to an individual patient),
- the health system (i.e., the structures, processes, and incentives that shape the clinical care environment; this includes major health domains such as public health, population health, personal health, health professional education, and clinical research, in addition to clinical care),

*A “holy grail” of clinical informatics is scalable, interoperable clinical decision support.*

according to

Kensaku Kawamoto

HL7 Work Group Meeting,

San Diego, CA, September 2011

Affiliations of the authors: Department of Medical Informatics, University of Utah (RMG), Salt Lake City, UT; Regenstrief Institute and Indiana Health Information Exchange (JMO), Indianapolis, IN; American Medical Informatics Association (EBS, JJW, DED), Bethesda, MD; Arizona Emergency Medicine Research Center, University of Arizona (BSM), Tucson, AZ; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine (JHH), Philadelphia, PA; University of Virginia School of Medicine (DED), Charlottesville, VA.

The American Medical Informatics Association (AMIA) Board of Directors thanks the members of the Clinical Informatics Core Content team for their thoughtful and energetic discussions that resulted in this document. Team members included: Joan S. Ash, PhD, MBA; James J. Cimino, MD; H. Dominic Covey, MS; Reed M. Gardner (Chair), PhD; John H. Holmes, PhD; Nancy C. Nelson, MS; J. Marc Overhage, MD, PhD (Vice Chair); Charles Safran, MS, MD; Richard N. Shiffman, MD, MChS; and Heiko Spallek, DMD, PhD. AMIA acknowledges the contributions of over fifty reviewers whose input strengthened the core content. AMIA thanks the Robert Wood Johnson Foundation for generously supporting this project.

Correspondence: Elaine B. Steen, MA, American Medical Informatics Association, 4915 St. Elmo Avenue, Suite 401, Bethesda, MD 20814; e-mail: <elaine.steen@msn.com>.

Received for review: 10/21/2008; Accepted for publication: 12/05/2008


---

## Fuzzy Arden Syntax: Modelling uncertainty in medicine

- **linguistic uncertainty**
    - due to the unsharpness (fuzziness) of boundaries of linguistic concepts; gradual transition from one concept to another
    - modeled by fuzzy sets, e.g., fever, increased glucose level
  - **propositional uncertainty**
    - due to the uncertainty (or incompleteness) of medical conclusions; includes definitional and causal, statistical and subjective relationships
    - modeled by truth values between zero and one, e.g., usually, almost confirming
-

---

## Crisp sets vs. fuzzy sets




yes/no decision

$$U = [0, 120]$$

$$Y \subseteq U \text{ with } Y = \{(\chi_Y(x)/x) \mid x \in U\}$$

$$\chi_Y: U \rightarrow \{0, 1\}$$

$$\chi_Y(x) = \begin{cases} 0 & x > \text{threshold} \\ 1 & x \leq \text{threshold} \end{cases} \quad \forall x \in U$$



gradual transition

$$U = [0, 120]$$

$$Y \subseteq U \text{ with } Y = \{(\mu_Y(x)/x) \mid x \in U\}$$


$$\mu_Y: U \rightarrow [0, 1]$$

$$\mu_Y(x) = \begin{cases} \frac{1}{1 + (0.04 x)^2} & x > \text{threshold} \\ 1 & x \leq \text{threshold} \end{cases} \quad \forall x \in U$$

---


---

## Crisp sets vs. fuzzy sets



*"arbitrary" yes/no decisions*

- cause of unfruitful discussions
- often simply wrong



*"intuitive" gradual transitions*


---

---

## Clinical concepts and relationships between them

$$(s_1 \wedge s_2) \vee \neg s_3 \xrightarrow[t]{\text{truth value}} D$$

DoC





---

# Arden Syntax

---

---

## What is Arden Syntax ?

- ... a language used for representing and sharing medical knowledge.
  - ... used for sharing of computerized health knowledge bases across personnel, information systems, and institutions.
  - ... organized using modules, while each module, referred to as a Medical Logic Module (MLM), contains sufficient knowledge to make a single decision.
  - ... an executable format which can be used by clinical decision support systems.
-

---

## Arden Syntax – Fundamentals I

- In Arden Syntax, medical knowledge is arranged within Medical Logic Modules (MLMs)
- Each MLM represents sufficient knowledge to make a single clinical decision
- One or more MLMs are stored within a file that has the extension “.mlm”
- Each MLM is well organized and structured into categories and slots with specific content
- An MLM is composed of slots, grouped into the following **four** required **categories: maintenance, library, knowledge, and resources**
- Categories must appear in the correct order
- Within each category is a set of **slots** that must appear in the correct order, too

```
maintenance:
  title:      [TITLE_(needed)];;
  mlmname:    [MLM-NAME_(needed)];;
  arden:      Version 2.5;;
  version:    [MLM-VERSION_(needed)];;
  institution: [INSTITUTION_(needed)];;
  author:     ;;
  specialist: ;;
  date:       [DATE];;
  validation: testing;;
library:
  purpose:    ;;
  explanation: ;;
  keywords:   ;;
  citations:  ;;
  links:      ;;
knowledge:
  type:       data_driven;;
  data:       ;;
  priority:   ;;
  evoke:      ;;
  logic:
    conclude true;
  ;;
  action:
  ;;
  urgency:    ;;
end:
```

---

---

## Arden Syntax – Fundamentals II

- MLMs are working in close contact with their host system. Ways of interaction are:
    - **Input:** By calling an MLM, an input parameter can be committed
    - **Curly Brace Expressions:** So called “curly brace expressions” implement a special kind of dynamic interaction between MLMs and host systems
    - **Write Statements:** Texts can be written to destinations that are maintained by the host system
    - **Output:** Analogous to the input parameter, data can be committed from the MLM to the host system after the execution of the MLM has finished
  - In order to start the execution of an MLM, an engine is needed that handles communication with the host system and can tell which of the MLMs are available
  - Ways to start running an MLM:
    - **MLM call:** An MLM is directly called
    - **Event call:** Any MLM that listens to a specific event is executed
-

---

## Sample MLM

- Some of the operators and concepts can be seen in the following sample MLM that calculates the body mass index (BMI) of a patient:

```
maintenance:
  title: simple body mass index;;
  mlmname: BMI_HowTo;;
  arden: Version 2.7;;
  version: 1.00;;
  institution: Medexter Healthcare GmbH;;
  author: Karsten Fehre;;
  specialist: ;;
  date: 2010-09-09;;
  validation: testing;;
library:
  purpose: body mass index;;
  explanation: calculation of body mass index;;
  keywords: BMI, body mass index;;
  citations: ;;
  links: http://en.wikipedia.org/wiki/Body\_mass\_index;;
```

---

## Sample MLM (cont.)

```
knowledge:
  type: data_driven;;
  data:

    // MLM that contains the interface definition "LET get_birth BE INTERFACE {Patient.dateOfBirth}; "
    mlmImport      := MLM 'interface_birthday_definition';

    // include
    include mlmImport;

    mlmForReadSize := MLM 'read_Size_MLM'; // MLM which can read the current size of the patient from the DB

    LET patientID BE argument; // the patient ID is passed to the MLM

    LET birth      BE CALL get_birth WITH patientID; // call the interface with the passed patient ID

    // read all measured weights from the database
    LET weights    BE READ {SELECT measured_weight FROM DB WHERE patID = patientID };

    LET userEvent BE EVENT {getBMI};

    // object declaration
    bmiResult := object [bmi, classification];

;;
priority: ;;
evoked:
  userEvent;
;;
```

---

---

## Sample MLM (cont.)

```
logic:
  result := new bmiResult; // create an empty result object

  weight := latest of weights; // get the latest weight from the list

  size := call mlmForReadSize with patientID; // get the size of the patient calculated by another MLM

  result.bmi := weight / (size ** 2); // calculation of BMI
  age := currenttime - birth; // calculation of AGE

  // classification - the classification is only valid for patients older than 19
  if the age is less than 19 years then result.classification := null;
  elseif the result.bmi is less than 18.5 then result.classification := localized 'under';
  elseif the result.bmi is less than 25 then result.classification := null;
  else let the result.classification be localized 'over';
  endif;

  result.bmi := result.bmi formatted with localized 'msg'; // construct the localized message

  if (time of weight) is before (currenttime - 6 months) then
    conclude false; //no bmi calculation if the latest measure was 6 months ago
  else
    conclude result.classification is present ; // if there is a classification, execute the action slot
  endif;

;;
```

---

---

## Sample MLM (cont.)

```
action:

    write result.bmi || result.classification || "."; // return result

    return result;
;;
urgency: ;;
resources:
    default: de;;
    language: en
        'msg' : "The patient's BMI %.1f is not in the normal range and is classified as ";
        'under' : "Underweight";
        'over' : "Overweight"
    ;;
    language: de
        'msg' : "Der BMI %.1f des Patienten ist nicht im normalen Bereich und wird klassifiziert als ";
        'under' : "Untergewicht";
        'over' : "Übergewicht"
    ;;
end;
```

---



---

## Arden Syntax – Fundamentals III

- Data types
  - Statements, expressions (assignments, loops, variables, constants, objects)
  - Operators
    - List operators
    - Logical operators
    - Comparison operators
    - String operators
    - Arithmetic operators
    - Temporal operators
    - Aggregation operators
    - Time and object operators
-

---

## Primary Time

- In addition to its value part each data value has a **primary time** part and an applicability
  - Primary time represents the value part's time of creation or measurement
  - By default, primary time is `null`
  - Can be accessed using the `time` operator  
`2011-03-15T00:00:00 := 2 days AFTER 2011-03-13T00:00:00`
  - Database query results should contain both, the value and the primary time
    - Might be the time when a blood test was drawn from the patient
    - Might be the time when a medication order was placed
    - Which time of a database entry is taken as primary time is left to the used Arden Syntax implementation
-

---

## History

- A first draft of the standard was prepared at a meeting at the Arden Home-stead, New York, in 1989. Arden Syntax was previously adopted as a standard by the American Society for Testing and Materials (ASTM) as document E 1460, under subcommittee E31.15 Health Knowledge Representation.
- 1992: Arden Syntax version 1.0
- 1998: sponsorship moved to HL7 International (Arden Syntax Work Group)
- 1999: Arden Syntax version 2.0 adopted by HL7 and the American National Standards Institute (ANSI)
- 2014: Arden Syntax version 2.10



Arden House  
AMERICA'S FIRST CONFERENCE CENTER



---

## History

| Version     | Year | Important changes  |
|-------------|------|--|
| <b>2.1</b>  | 2002 | new string operators; reserved word "currenttime" returns the system time  |
| <b>2.5</b>  | 2005 | object capabilities: create and edit objects; XML representation of MLMs (except logic, action and data slot)  |
| <b>2.6</b>  | 2007 | UNICODE encoding; additional resources category to define text resources for specific languages; time-of-day and day-of-week data types; "localized" operator to access texts in specific languages  |
| <b>2.7</b>  | 2008 | enhanced assignment statement; extended "new" operator to allow easy and flexible object instantiation   |
| <b>2.8</b>  | 2012 | additional operators for list manipulation; operators to manipulate parts of given date and time values; switch statements; keyword "breakloop" for aborting a loop; number of editorial corrections |
| <b>2.9</b>  | 2013 | fuzzification: fuzzy data types and fuzzy sets; adjustment of all available operators to be able to handle fuzzy data types  |
| <b>2.10</b> | 2014 | XML representation of whole MLMs (including logic, action and data slot)   |

---

---


# Fuzzy Arden Syntax

---


---

## Fuzzy Sets – Background I

- **Crisp** border
  - Defines a **sharp** border
  - Checking if a given measurement is greater or less than the defined crisp border results in either true or false
  - Borderline cases are not detected




- **Fuzzified** border
  - Defines a **gradual** border
  - Checking if a given measurement is greater or less than the defined fuzzified border results in a truth value between 0 and 1
  - Borderline cases are detected
  - Weighted results for borderline cases, all other are as usual



---


## Fuzzy Sets – Background II



- Function that maps a given data value to a truth value between 0 and 1
  - A **fuzzy set** represents a linguistic/clinical concept with fuzzy (non-sharp) boundaries
-

---

## Fuzzy Sets



- Definition of a fuzzy set

```
Fuzzyset_u := FUZZY SET (18.5,0), (19.5,1), (24,1), (25,0);
```

```
Fuzzyset_v := 7 fuzzified by 2;
```

- Fuzzy set based on other data types

```
Fuzzyset_duration := FUZZY SET (3 days,0), (10 days,1), (20 days,1), (25 days,0);
```

```
simple := 2009-10-10 fuzzified by 12 hours;
```

```
complex := FUZZY SET (2009-10-10,0), (2009-10-11,1), (2009-11-10,1), (2009-  
- 11-11,0);
```

---



---

## Fuzzy Sets – Example I

- **Usual** Arden Syntax

```
fever_limit := 38;  
temperature := 37.9;
```

```
message := "patient has no fever";  
IF temperature > fever_limit THEN  
    message := "patient has fever";  
END IF
```

- Result message: "patient has no fever"
- Borderline case is not detected

- **Fuzzy** Arden Syntax

```
fever_limit := FUZZY SET (37.5,0), (38,1);  
temperature := 37.9;
```

```
message := "patient has no fever";  
IF temperature > fever_limit THEN  
    message := "patient has fever";  
END IF
```

- Result message: "patient has fever" (with applicability 0.8)

---

## Applicability

- Arden Syntax contains two types of fuzziness:
    - Data types: for explicit calculations e.g., truth value, fuzzy set
    - Applicability: for weighting MLM evaluation and weighting of branches
  - All simple data types are endowed with information concerning the degree of **applicability**
  - Stores a truth value that refers to the degree to which it is reasonable to use the value of a variable
  - Default applicability is 1 and the applicability is never null
  - Can be accessed using the `applicability` operator
  - If-then statements with a condition that evaluates to a truth value  $[0,1]$  result in a split of the MLM execution
    - Each branch will be executed under corresponding applicability
    - The applicability is implicit attached to each variable of the branch
-


---

## Statements – If-Then-ElseIf – Fuzzy Condition


### Source

```
maintenance: [...]  
knowledge: [...]  
logic:  
  //define linguistic variable BMI  
  [...]  
  myBMI := 24.8;  
  x := myBMI <= BMI.overweight;  
  if x then  
    // this branch is executed  
    // with applicability 0.8  
    <then_block>  
  else  
    // this branch is executed  
    // with applicability 0.2  
    <else_block>  
  endif;  
[...]  
end:
```

### Arden Syntax



### Fuzzy Arden Syntax




---

## Statements – If-Then-Aggregate

```
if x then
    <then_block>
else
    <else_block>
endif AGGREGATE;
```

- Combination of the variable values in each execution branch according to their applicability
- Aggregations are common in fuzzy control



---

# ArdenML

---

---

## **ArdenML: Objectives and applications**

- Provide a complete XML schema for version 2.10 of the Arden Syntax to express MLMs in XML
- Thus, Arden Syntax is now compatible with all other HL7 standards based on XML (HL7 version 3, VmR, and others)
- Further benefit: To be able to use available XML tools

---


## ArdenML: Example

```
<Library>
  <Purpose>Test</Purpose>
  <Explanation></Explanation>
  <Keywords></Keywords>
</Library>
<Knowledge>
  <Type>data_driven</Type>
  <Data></Data>
  <Evoke></Evoke>
  <Logic>
    <Assignment>
      <Identifier var='var1' />
      <Assigned>
        <Value otype='time'>1990-03-15T15:00:00</Value>
      </Assigned>
    </Assignment>
    <Assignment>
      <Identifier var='res1' />
      <Assigned>
        <ReplaceYearWith>
          <Identifier var='var1' />
          <Value otype='number'>2011</Value>
        </ReplaceYearWith>
      </Assigned>
    </Assignment>
    <Assignment>
      <Identifier var='res2' />
      <Assigned>
        <ReplaceYearWith>
          <Identifier var='var1' />
          <List>
            <Value otype='number'>2011</Value>
            <Value otype='number'>2010</Value>
          </List>
        </ReplaceYearWith>
      </Assigned>
    </Assignment>
  </Logic>
</Knowledge>
```

---

---

## Cross compilation/transformation of Arden Syntax to/from ArdenML





---

# Integration

---

---

## How to execute MLMs

- **MLM calls:** When the MLM call statement is executed, the current MLM is interrupted, and the named MLM is called; parameters are passed to the named MLM

```
/* Define find_allergies MLM */  
find_allergies := MLM 'find_allergies';  
(allergens, reactions) := call find_allergies;
```


- **Event calls:** When the event call statement is executed, the current MLM is interrupted, and all the MLMs whose evoke slots refer to the named event are executed; parameters are passed to the named MLMs

```
allergy_found := EVENT {allergy found};  
reactions := call allergy_found;
```

---


---

## How to execute MLMs – Arden Syntax Engine




---

## How to execute MLMs – Web Service Interfaces



## How to execute MLMs – Web Service Usage



**teleiatros®**  
telemedical decision support

**Hepaxpert/Interpretation**  
Knowledge-based interpretation of hepatitis A, B, and C serology

|   |  |  |
|---|--|--|
| <div style="border: 1px solid black; padding: 2px; margin-bottom: 5px;"> <b>Fall/Außerhalb</b> </div> <div style="border: 1px solid black; padding: 2px; margin-bottom: 5px;"> <b>Druckadressaten</b> </div> <div style="border: 1px solid black; padding: 2px; margin-bottom: 5px;"> <b>Dokumentstatus</b> </div> <div style="border: 1px solid black; padding: 2px; margin-bottom: 5px;"> <b>Externe Ärzte</b> </div> <div style="border: 1px solid black; padding: 2px;"> <b>Kontaktdaten</b> </div> | <b>Patient:</b> <span style="background-color: black; color: white; padding: 0 10px;"> </span><br><b>Fall:</b> <span style="background-color: black; color: white; padding: 0 10px;"> </span><br><b>Bewegung:</b> <span style="background-color: black; color: white; padding: 0 10px;"> </span> | <b>Patient:</b> <span style="background-color: black; color: white; padding: 0 10px;"> </span><br><b>Gesamter Patient</b><br><br><b>Gesamter Patient</b> |
|---|--|--|

**Schema:** SOP Nr. 2 - Dacarbazine 800mg
✔ - in klinischer Valid.

### Pra-Chemotherapie Checkliste

| Text                      | Bemerkung   | 14.04.2011   |
|---------------------------|-------------|--|
| Verabreichungen           |             |  |
| ▼ Labor                   |             | 14.04.2011   |
| ▼ Blutbild                |             |  |
| • Erythrozyten            | > 4.0 T/l   | 4.1  |
| • Hämoglobin              | > 12.0 g/dl | 12.3   |
| • Leukozyten              | > 3.0 G/l   | 3  |
| • Thrombozyten            | > 100 G/l   | 105  |
| ▼ Metaboliten             |             |  |
| • Creatinin               | < 1.2 mg/dl | 1.3  |
| ▼ Entzündungsparameter    |             |  |
| • CRP                     | < 1 mg/dl   | 1  |
| ▼ Allgemeinzustand        |             |  |
| • ECOG State              |             | 1  |
| ▼ Wissensbasiertes System |             | <span style="border: 1px solid black; padding: 2px 5px;">Prüfen</span> |
| • Empfehlung              |             |  |
| • Status                  |             |  |
| • Erklärung               |             |  |
| ▼ Sonstiges               |             |  |
| • Bemerkung               |             |  |
|                           |             |  |
| • Freigabe<br>• Storno    |             |  |

FAQs

Scientific development

Scientific publications

Feedback

English version

Deutsche Version

Hepatitis A serology

anti-HAV

positive

IgM anti-HAV

positive

HAV-RNA

positive

Hepatitis B serology

HBSAg

positive

anti-HBc

positive

anti-HBe

positive

IgM anti-HBc

positive

HBeAg

positive

anti-HBe

positive

anti-HBs titre

U/l

Hepatitis C serology

anti-HCV

positive

HCV-RNA

positive

Center

Hepaxpert/Interp

Knowledge based Interpretation of

Input of test results

Hepatitis A serology

anti-HAV

positive

IgM anti-HAV

positive

HAV-RNA

positive

Hepatitis B serology

HBSAg

positive

© 2007-2012 Mediatech. All rights reserved. | Terms of Use | Privacy Policy

© 2007-2012 Medexer. All rights reserved. | [Terms of Use](#) | [Privacy Policy](#)

[illegible]


---

## How to get data into MLMs

- MLM and event calls
  - Provide data to an other MLM
  - Read data provided to the actual MLM
  - Return data to calling MLM or instance
- Curly brace expressions
  - Read data from external data sources
  - Write data to external data sources
  - Call external applications or interfaces

---

## How to get data into MLMs – Curly Brace Expressions



---

## Types of Integration I

- I. MLM/event calls together with data
  - through web-services (intranet/Internet)



---

## Types of Integration II

II.

MLM/event calls

- through web-services

data access from inside MLMs

- through server connector as
  - + ... {web-services}
  - + ... {SQL statements}
  - + ... {...}

---

## Types of Integration III

III.

Data warehouse + Arden Syntax server = autonomous CDS system

- data provided through HL7/XML/batch/... communication
- full process control (MLM triggering)
- additional analytics, reporting, benchmarking
- full legal control (legal obligation to retain data, burden of proof)

---

## Clinical decision support with Arden Syntax

- CDS platforms
    - based on Arden Syntax and Fuzzy Arden Syntax
      - \* with data (sometimes) and knowledge services center and extended interoperability (web services, XML data interfaces, libraries, HL7)
  - integrated into or interconnected with
    - PDMSs (ICCA by Philips, MetaVision by IMDsoft)
      - \* Monitoring, reporting, and benchmarking of ICU-acquired infections (ICUs and NICUs)
    - ICM (by Dräger)
      - \* ICU decision support modules (Universitätsklinikum Erlangen)
    - i.s.h.med HIS and Soarian HIS (by Siemens AG)
      - \* dosing of immunosuppressive drugs for kidney transplant patients
      - \* prediction of metastases in melanoma patients
      - \* standard operating procedures for chemotherapy treatment of melanoma patients
      - \* hepatitis serology test interpretation
    - medico//s HIS (by Siemens AG)
      - \* laboratory-based clinical reminders
    - Epic
      - \* clinical decision support
    - VistA HIS (by Department of Veterans Affairs)
      - \* service-oriented, standards-based CDS (clinical reminders and patient report cards)
    - Monitoring adverse drug events (project with Salzburger Universitätsklinikum)
    - Teleiatros, iPhone, iPad
      - \* remote CDS, mHealth
-

from 2011-12-01

to 2011-12-05

show

clinic

show department diagram

fixed table width


| department / patient |  |
|----------------------|--|
| Stat. 11857          |  |
| Stat. 11888          |  |
| Stat. 11889          |  |
| Stat. 11890          |  |
| Stat. 12043          |  |
| Stat. 12045          |  |
| Stat. 12074          |  |
| Stat. 12075          |  |
| Stat. 83644          |  |
| Stat. 62354          |  |
|                      |  |
| Pat. 145107          |  |
| Pat. 145132          |  |
| Pat. 145114          |  |
| Pat. 145126          |  |
| Pat. 145124          |  |
| Pat. 145121          |  |
| Pat. 145119          |  |
| Pat. 145109          |  |
| Pat. 145130          |  |
| Pat. 145112          |  |
| Pat. 145128          |  |
|                      |  |
| Stat. 62621          |  |
| Stat. 11408          |  |
| Stat. 30488          |  |
| Stat. 88879          |  |

| Pat. 145114                               |  |
|---|--|
| 2011-12-14 (Stat. 62354) no data          |  |
| 2011-12-13 (Stat. 62354) no data          |  |
| 2011-12-12 (Stat. 62354) no data          |  |
| A 2011-12-11 (Stat. 62354)                |  |
| A 2011-12-10 (Stat. 62354)                |  |
| A 2011-12-09 (Stat. 62354)                |  |
| A 2011-12-08 (Stat. 62354)                |  |
| A 2011-12-07 (Stat. 62354)                |  |
| A 2011-12-06 (Stat. 62354)                |  |
| A 2011-12-05 (Stat. 62354)                |  |
| A 2011-12-04 (Stat. 62354)                |  |
| A 2011-12-03 (Stat. 62354)                |  |
| BSI-3 (KISS)                              |  |
| BSI-3 (Alert)                             |  |
| klin. Anzeichen f. Pneumonie (KISS)       |  |
| klin. Anzeichen f. Pneumonie (Alert)      |  |
| 2 klin. Anzeichen f. Sepsis (KISS)        |  |
| 2 klin. Anzeichen f. Sepsis (Alert)       |  |
| 2 Labor- und klin. Anz. f. Sepsis (KISS)  |  |
| 2 Labor- und klin. Anz. f. Sepsis (Alert) |  |
| andere Sepsiszeichen (KISS)               |  |
| andere Sepsiszeichen (Alert)              |  |
| laborchem. Zeichen für Pneumonie (Alert)  |  |
| laborchem. Zeichen für Entzündung (Alert) |  |
| erhöhter Beatmungsaufwand (Alert)         |  |
| erhöhtes CRP (abs., Alert)                |  |
| eitriges Trachealsekret                   |  |
| imp.: kein Erreger in nicht-Blut          |  |
| imp.: nicht beatmet (KISS)                |  |
| imp.: Antiinfektivum                      |  |
| imp.: ZVK (Zentralvenenkath.)             |  |
| A 2011-12-02 (Stat. 62354)                |  |
| A 2011-12-01 (Stat. 62354)                |  |
| 2011-11-30 (Stat. 62354)                  |  |
| 2011-11-29 (Stat. 62354)                  |  |
| 2011-11-28 (Stat. 62354)                  |  |
| 2011-11-27 (Stat. 62354) no data          |  |
| 2011-11-26 (Stat. 62354) no data          |  |
| 2011-11-25 (Stat. 62354) no data          |  |

| BSI-3 (KISS)                             |  |
|--|--|
| UND                                      |  |
| imp.: keine Blutkultur                   |  |
| imp.: kein Erreger in nicht-Blut         |  |
| Antiinfektiva für 5 Tage                 |  |
| 2 Labor- und klin. Anz. f. Sepsis (KISS) |  |
|  |  |
| 2 Labor- und klin. Anz. f. Sepsis (KISS) |  |
| MIND. 2 VON                              |  |
| pathol. Körpertemperatur                 |  |
| neue Hyperglykämie (KISS)                |  |
| ODER                                     |  |
| laborchem. Zeichen für Entzündung (KISS) |  |
| andere Sepsiszeichen (KISS)              |  |
|  |  |
| neue Hyperglykämie (KISS)                |  |
| UND                                      |  |
| NICHT                                    |  |
| Hyperglykämie (KISS) (t-1d)              |  |
| Hyperglykämie (KISS)                     |  |
|  |  |
| Hyperglykämie (KISS)                     |  |
| maximale Glukose                         |  |
|  |  |
| maximale Glukose                         |  |
| imp.: Glukose                            |  |
| imp.: Glukose                            |  |
| imp.: Glukose                            |  |
| imp.: Glukose                            |  |

# Moni output

Section of Moni screenshot for one ICU: Colors indicate patients with infection episodes, where change in color means change in data-definition compatibility





---

## Arden Syntax—integration of software

III.

Data warehouse + Arden Syntax server = autonomous CDS system

- data provided through HL7/XML/batch/... communication
- full process control (MLM triggering)
- additional analytics, reporting, benchmarking
- full legal control (legal obligation to retain data, burden of proof)

---

## First study:

⇒ 99 ICU patient admissions; 1007 patient days

HAI episodes correctly / falsely identified or missed by Moni-ICU

|                            | episode present<br>"gold standard"<br>(n= 19) | episode absent<br>"gold standard"<br>(n= 78) |
|----------------------------|---|--|
| episode present "Moni-ICU" | 16<br>(84%)                                   | 0<br>(0%)                                    |
| episode absent "Moni-ICU"  | 3<br>(16%)                                    | 78<br>(100%)                                 |

Time expenditure for both surveillance techniques

|            | conventional<br>surveillance | Moni-ICU<br>surveillance |
|------------|------------------------------|--------------------------|
| time spent | 82.5 h<br>(100%)             | 12.5 h<br>(15.2%)        |

Blacky, A., Mandl, H., Adlassnig, K.-P. & Koller, W. (2011) Fully Automated Surveillance of Healthcare-Associated Infections with MONI-ICU – A Breakthrough in Clinical Infection Surveillance. Applied Clinical Informatics 2(3), 365–372.

---



---

## Second study:

⇒ 93 ICU patient admissions; 882 patient days; 30 HAI episodes over complete or partial duration of stay; 76 stays with no HAI episodes

HAI episodes correctly / falsely identified or missed by Moni-ICU

|                 |    | <i>gold<br/>standard</i> |    |
|-----------------|----|--------------------------|----|
|                 |    | I+                       | I- |
| <i>Moni-ICU</i> | I+ | 26                       | 1  |
|                 | I- | 4                        | 75 |
|                 |    | 30                       | 76 |

sensitivity = 87%


- 3 false-negative pneumonias + 1 false-negative CVC-related infection due to missing microbiology

specificity = 99%

- 1 false-positive CVC-related infection because of a present concomitant leukemia (with leukocytosis)

---

## Two different hyperglycemia definitions



# Moni-NICU cockpit view

The interface displays patient data and clinical parameters for a specific patient (Pat. 1464848). The top navigation bar includes icons for Calculation, Surveillance, Report, Administration, Help, and Logout. The main area shows a list of patients on the left, a detailed view of the selected patient in the center, and a list of clinical parameters on the right.

from 2013-05-12 to 2013-05-12 show all parameters show department diagram fixed table width

| department / patient | Pat. 1464848                           | hyperglycemia (KISS)      |
|----------------------|--|---------------------------|
| Stat. 10865          | 2013-05-23 (Stat. 62354)               | maximal glucose 195 mg/dl |
| Stat. 10896          | 2013-05-22 (Stat. 62354)               |                           |
| Stat. 10897          | 2013-05-21 (Stat. 62354)               |                           |
| Stat. 10898          | 2013-05-20 (Stat. 62354)               |                           |
| Stat. 11051          | 2013-05-19 (Stat. 62354)               |                           |
| Stat. 11053          | 2013-05-18 (Stat. 62354)               |                           |
| Stat. 11082          | 2013-05-17 (Stat. 62354)               |                           |
| Stat. 11083          | 2013-05-16 (Stat. 62354)               |                           |
| Stat. 39690          | 2013-05-15 (Stat. 62354)               |                           |
| Stat. 62354          | 2013-05-14 (Stat. 62354)               |                           |
|                      | 2013-05-13 (Stat. 62354)               |                           |
|                      | 2013-05-12 (Stat. 62354)               |                           |
|                      | antiinfectives for 5 days 100 %DoC     |                           |
|                      | 1 clin. sign of sepsis (KISS) 100 %DoC |                           |
|                      | new hyperglycaemia (KISS) 100 %DoC     |                           |
|                      | hyperglycemia (KISS) 100 %DoC          |                           |
|                      | maximal glucose 195 mg/dl              |                           |
|                      | minimal VBG-BE 0.1 mval/...            |                           |
|                      | minimal VBG-PH 7.31                    |                           |
|                      | maximal VBG-PCO2 53.6 mmHg             |                           |
|                      | average respirator O2 21.45 % O...     |                           |
|                      | average FiO2 21.45 % F...              |                           |
|                      | maximal FiO2 25 % FiO2                 |                           |
|                      | average PIP 6.32 mbar                  |                           |
|                      | maximal PIP 25 mbar                    |                           |

## Regel zur Interpretation von klinisch relevanten Befunden (Regelprämissen bilden Äquivalenzklassen)

REGEL 103:

WENN eine der folgenden 100 Kombinationen zutrifft

| HBsAg | anti-HBs | anti-HBc | IgM-anti-HBc | HBeAg | anti-HBe |
|-------|----------|----------|--------------|-------|----------|
| +     | •        | +        | - ± •        | +     | - ± •    |
| +     | •        | +        | +            | +     | +        |

DANN

Das gleichzeitige Auftreten von HBe-Antigen und Anti-HBs-Antikörpern ist im natürlichen Verlauf einer Hepatitis-B-Virusinfektion ein **seltenes Ereignis**. Diese Befundkonstellation ist entweder auf (a) zirkulierende HBsAg-anti-HBs-Immunkomplexe, (b) auf eine Koinzidenz einer Hepatitis-B-Virusinfektion mit einer Hepatitis-B-Impfung oder Injektion von HB-Hyperimmunglobulin oder (c) eine Reinfektion mit einem Hepatitis-B-Virus mit unterschiedlichem HBsAg-Subtypus zurückzuführen. Blut und Sekrete (Speichel, Sperma, Muttermilch) solcher Patienten sind als **infektiös** anzusehen.

# Interpretation of hepatitis serology test results

## Hepaxpert/Interpretation Knowledge-based interpretation of hepatitis A, B, and C serology

### Interpretation

Benutzer: mxt [Logout](#)

### Hepatitis-A-Serologie

| Anti-HAV | IgM-anti-HAV     | HAV-RNA          |
|----------|------------------|------------------|
| positiv  | nicht untersucht | nicht untersucht |

Antikörper gegen das Hepatitis-A-Virus finden sich in drei unterschiedlichen Situationen: (a) bei rezenter Hepatitis-A-Virusinfektion (akute ikterische oder anikterische Hepatitis, stille Feiung oder Rekonvaleszenzstadium einer Hepatitis), (b) bei Immunität nach früherer Hepatitis-A-Virusinfektion oder (c) nach aktiver Impfung oder passiver Immunisierung mit Gammaglobulin.

### Hepatitis-B-Serologie

| HBsAg   | Anti-HBs | Anti-HBc       | IgM-anti-HBc |
|---------|----------|----------------|--------------|
| positiv | positiv  | positiv        | positiv      |
| HBsAg   | Anti-HBe | Anti-HBs Titer |              |
| positiv | positiv  | - - U/l        |              |

Das gleichzeitige Auftreten von HBe-Antigen und Anti-HBs-Antikörpern ist im natürlichen Verlauf einer Hepatitis-B-Virusinfektion ein seltenes Ereignis. Diese Befundkonstellation ist entweder auf (a) zirkulierende HBsAg-Anti-HBs-Immunkomplexe, (b) auf eine Koinzidenz einer Hepatitis-B-Virusinfektion mit einer Hepatitis-B-Impfung oder Injektion von HB-Hyperimmunglobulin oder (c) eine Reinfektion mit einem Hepatitis-B-Virus mit unterschiedlichem HBsAg-Subtypus zurückzuführen. Blut und Sekrete (Speichel, Sperma, Muttermilch) solcher Patienten sind als infektiös anzusehen.

### Hepatitis-C-Serologie

| Anti-HCV | HCV-RNA |
|----------|---------|
| positiv  | negativ |

Der erhobene Befund spricht für eine früher abgelaufene HCV-Infektion oder für eine Remission einer bestehenden HCV-Infektion. Bei klinischem Verdacht auf Hepatitis C sind Verlaufskontrollen indiziert. Das Blut solcher Personen ist hinsichtlich Hepatitis C als infektiös anzusehen.

### Wichtiger Hinweis

Die Verantwortung für Diagnose und Therapie eines Patienten trägt ausschließlich der behandelnde Arzt. Konsultieren Sie daher immer einen Arzt. Nur dieser kann die Hepaxpert-Interpretation in Einklang mit dem gesamten klinischen Bild des Patienten bringen.

### PROTEINDIAGNOSTIK

|     |          |           |      |
|-----|----------|-----------|------|
| CRP | 61.5 *** | 0.8 - 5.0 | mg/l |
|-----|----------|-----------|------|

### HORMONE

|     |      |           |      |
|-----|------|-----------|------|
| TSH | 3.00 | 0.2 - 3.5 | mU/l |
|-----|------|-----------|------|

### INFEKTIONSSEROLOGIE

|                |         |         |
|----------------|---------|---------|
| HIV-Antikörper | Negativ | Negativ |
|----------------|---------|---------|

### HEPATITIS-SEROLOGIE

|                   |                  |         |
|-------------------|------------------|---------|
| Anti-HAV-IgM      | Negativ          | Negativ |
| Anti-HAV          | <b>Positiv</b> * | Negativ |
| HBsAG             | Negativ          |         |
| Anti-HBs          | Negativ          |         |
| Anti-HBs (quant.) | 1.42             | U/l     |
| Anti-HBc          | Negativ          |         |
| Anti-HCV          | Negativ          | Negativ |

test results

#### Medizin. Kommentar/Interpretation:

##### HEPATITIS-SEROLOGIE:

Positive Gesamtkörper (Anti-HAV) bei negativen IgM-anti-HAV Antikörpern beweisen Immunität gegen das Hepatitis-A-Virus und schließen eine rezente Hepatitis A aus. Diese Immunität kann entweder durch eine frühere Infektion natürlich erworben oder aber durch aktive Impfung oder passive Immunisierung induziert sein.

Anti-HBs Titer: 1 Units/Liter

Eine bestehende oder frühere Hepatitis-B-Virusinfektion kann (mit Ausnahme des Inkubationsstadiums) ausgeschlossen werden. Es besteht keine Immunität gegen das Hepatitis-B-Virus. Das Blut kann hinsichtlich Hepatitis B als nicht infektiös angesehen werden. Impfeempfehlung: Die Indikation zur Hepatitis-B-Impfung vorausgesetzt, soll in diesem Fall bei einem Ungeimpften die Grundimmunisierung (entsprechend dem Schema des jeweiligen Impfstoffes) durchgeführt und - zur Abschätzung der Immunantwort - 1-2 Monate nach der letzten Teilimpfung der Anti-HBs Titer bestimmt werden. Bei einem Geimpften mit abgeschlossener Grundimmunisierung soll unverzüglich eine Booster Injektion gegeben und - falls der Verdacht eines ablow responders/E besteht - eine Titerkontrolle 2 Monate nach dem Booster erhoben werden.

interpretation

# Hepaxpert/Interpretation in Soarian

The screenshot displays the SIEMENS Soarian interface. At the top, it shows 'SIEMENS Dr. Franz Hubert, UKER'. A red circle highlights a patient entry in the list: '7-F Mahler, Sybille' with a note '23.06.2005 12:48 Neue Hepatitis C Serologie liegt vor'. A red oval highlights a 'Warnungsbeschreibung' (Warning Description) dialog box. The dialog box contains the following information:

**Warnungsbeschreibung -- Web Page Dialog**

Mahler, Sybille  
W 61 j Aufnahme Nr. Pat.Nr. 5785747564744 Stat. UKER CH  
B6 7-F

**Warnung**

Datum: 23.06.05 12:52

Es besteht eine rezente oder chronisch protrahierte HCV-Infektion. Gegebenenfalls (bei antiviraler Therapie) ist die Bestimmung des Genotypus und der Replikationsrate zweckm?g. Das Blut solcher Personen ist als infekti?es anzusehen.

Schlie?en Hilfe

Below the dialog box, a table lists patients:

| UKER | CH B6 | 4-T     | Abrend, Paula    | 61 | W     |  |
|------|-------|---------|------------------|----|-------|--|
| UKER | CH B6 | 5-F     | Berger, Klaus    | 81 | M VIP |  |
| UKER | UR U2 | Bett 01 | flunder, Florian | 49 | M     |  |
| UKER | CH B2 | Bett 04 | Fritsche, Andrea | 40 | W     |  |
| UKER | CH B6 | 2-T     | Geiger, Heinrich | 72 | M     |  |
| UKER | CH B1 | Bett 01 | Hansen, Hans     | 71 | M     |  |
| UKER |       | Bett 06 | Leifeld, Norbert | 50 | M     |  |
| UKER | CH B6 | 7-T     | Linner, Patricia | 65 | W     |  |
| UKER | CH B6 | 7-F     | Mahler, Sybille  | 61 | W     |  |
| UKER | CH B2 | Bett 07 | Masuhr, Tanja    | 83 | W     |  |
| UKER | CH B6 |         | Meyer, Laurenz   | 57 | M     |  |
| UKER | CH B6 | 1-F     | M?ller, Dieter   | 60 | M     |  |
| UKER | CH B6 | 6-F     | Pauli, Inge      | 81 | W     |  |

At the bottom left, there are tabs for 'KLINISCHE DOKUMENTATION', 'MEDIKATION', 'AUFTR?GE ZUR FREIGABE', 'AUFTR?GE ZUR KENNTNISNAHME', and 'KONSULTATIONEN'. The 'KLINISCHE DOKUMENTATION' tab is selected, showing a value of '22'.

# ORBIS Experte: Hepatitis serology diagnostics

ORBIS

Datei Bearbeiten Fenster Extra ?

← → 📁

Übersichten

Station

Funktionsbereich

OP-Bereich

Expertensystem

Experte

Hepaxpert III

Thyrexpert

RheumExpert

geöffnete Akten

Bauer, Mathias

Diagnosen

Prozeduren

Kumulativbefund Labor

Krankengeschichte

Abrechnung

DRG Workplace

Fieberkurve

ICU-Scoring

Interne Leistungen

Zusatzinfos

Hepaxpert III

Hep. A

Hep. B

Hep. C

|              |             |               |                |          |             |
|--------------|-------------|---------------|----------------|----------|-------------|
| Anti-HAV     | Negativ     | Anti-HBs      | Positiv        | Anti_HCV | Positiv     |
| IgM anti-HAV | Positiv     | Anti-HBs Titr | 50             | HCV_RNA  | Grenzwertig |
| HAV          | Grenzwertig | HBsAg         | Positiv        |          |             |
|              |             | Anti-HBc      | Negativ        |          |             |
|              |             | IgM_anti_HB   | Negativ        |          |             |
|              |             | HbeAg         | Positiv        |          |             |
|              |             | Anti_HBe      | Nicht gemessen |          |             |

Ergebnisse

Hepatitis A

Der Befund enthält Widersprüche, da definitionsgemäß bei Vorliegen von IgM-anti-HAV-Antikörpern auch die Gesamtkörper Anti-HAV positiv sein müßten.

Rücksprache mit dem Laborleiter wird empfohlen. Zur Kontrolle des nicht eindeutig negativen oder positiven Befundes wird neuerliche Materialeinsendung empfohlen.

Hepatitis B

Das gleichzeitige Auftreten von HBe-Antigen und Anti-HBs-Antikörpern ist im natürlichen Verlauf einer Hepatitis-B-Virusinfektion ein seltenes Ereignis. Diese Befundkonstellation ist entweder auf (a) zirkulierende HBsAg-Anti-HBs-Immunkomplexe, (b) auf eine Koinzidenz einer Hepatitis-B-Virusinfektion mit einer Hepatitis-B-Impfung oder Injektion von HB-Hyperimmunglobulin oder (c) eine Reinfektion mit einem Hepatitis-B-Virus mit unterschiedlichem HBsAg-Subtypus zurückzuführen. Blut und Sekrete (Speichel, Sperma, Muttermilch) solcher Patienten sind als infektiös anzusehen.

Hepatitis C

Es besteht eine rezente oder chronisch persistierende oder eine früher abgelaufene Hepatitis-C-Virusinfektion. Die Bestimmung von HCV-RNA bringt zusätzliche Information. Das Blut solcher Personen ist hinsichtlich Hepatitis C als infektiös anzusehen.

Zur Kontrolle des nicht eindeutig negativen oder positiven Befundes wird neuerliche Materialeinsendung empfohlen.

10.11.2005 13:26:54 DEMO -05.03.29.44

IM/ST1 FLEMING

# Interpretation of hepatitis serology test results

Carrier 11:50 AM 100%

## Hepaxpert/Interpretation

Knowledge-based interpretation of hepatitis A, B, and C serology

### Input of test results

**Hepatitis A serology**

anti-HAV ☒ positive ☐ negative ☐ borderline ☐ not tested

IgM anti-HAV ☐ positive ☒ negative ☐ borderline ☐ not tested

HAV-RNA ☐ positive ☒ negative ☐ borderline ☐ not tested

**Hepatitis B serology**

HBsAg ☐ positive ☒ negative ☐ borderline ☐ not tested

anti-HBs ☐ positive ☒ negative ☐ borderline ☐ not tested

anti-HBc ☒ positive ☐ negative ☐ borderline ☐ not tested

IgM anti-HBc ☒ positive ☐ negative ☐ borderline ☐ not tested

HBeAg ☐ positive ☒ negative ☐ borderline ☐ not tested

anti-HBe ☐ positive ☒ negative ☐ borderline ☐ not tested

anti-HBs titre  U/I

**Hepatitis C serology**

anti-HCV ☒ positive ☐ negative ☐ borderline ☐ not tested

HCV-RNA ☐ positive ☐ negative ☐ borderline ☒ not tested

[Submit](#)

© 2007–2011 Medxter. All rights reserved.

Carrier 11:45 AM 100%

## Hepaxpert/Interpretation

Knowledge-based interpretation of hepatitis A, B, and C serology

### Interpretation

**Hepatitis A serology**

anti-HAV **positive** IgM anti-HAV HAV-RNA **negative**

Positive results for total anti-HAV antibodies in combination with negative results for IgM anti-HAV antibodies indicate immunity to the hepatitis virus A and exclude the possibility of a recent hepatitis A. This immunity may either have been acquired naturally through an earlier infection or it may have been induced by active vaccination or passively acquired immunization.

**Hepatitis B serology**

HBsAg **negative** anti-HBs **negative** anti-HBc **positive** IgM anti-HBc **negative** HBeAg **negative** anti-HBe **negative** anti-HBs titre **positive**

This constellation of findings (positive IgM anti-HBc antibodies with negative HBs- and HBe-antigen and negative anti-HBs and anti-HBe antibodies) occurs in the course of acute hepatitis B and is characteristic of the seroconversion both of HBs-antigen to anti-HBs and of HBe-antigen to anti-HBe antibodies. This stage may be regarded as a favorable prognostic sign with a view to a non-chronic course of the disease. Blood and secretions (saliva, sperm, breast milk) of the patient are to be considered infectious.

**Hepatitis C serology**

anti-HCV **positive** HCV-RNA **not tested**

There is a recent or chronic persisting or an earlier hepatitis C virus infection. An additional test for HCV-RNA adds further information. Blood of such patients may be considered as infectious with regard to hepatitis C.

**Important Notice**

The attending physician alone is responsible for the patient's diagnosis and therapy. Therefore, contact a doctor at all times. Only the doctor will be able to align the Hepaxpert interpretation with the full clinical picture of the patient.

[Reset](#)

© 2007–2011 Medxter. All rights reserved.

Carrier 11:47 AM

[Reset](#) Hepatitis B Serology [Submit](#)

Parameters

HBsAg **negative**

anti-HBs **negative**

anti-HBc **positive**

IgM anti-HBc **positive**

HBeAg **negative**

anti-HBe **negative**

anti-HBs titre **not tested**

[A](#) [B](#) [C](#) [i](#)  
Hepatitis Hepatitis Hepatitis Info

Carrier 11:48 AM

[Reset](#) Hepatitis B Serology [Submit](#)

anti-HBs titre **not tested**

Results

This constellation of findings (positive IgM anti-HBc antibodies with negative HBs- and HBe-antigen and negative anti-HBs and anti-HBe antibodies) occurs in the course of acute hepatitis B and is characteristic of the seroconversion both of HBs-antigen to anti-HBs and of HBe-antigen to anti-HBe antibodies. This stage may be regarded as a favorable prognostic sign with a view to a non-chronic course of the disease. Blood and secretions (saliva, sperm, breast milk) of the patient are to be considered infectious.

[A](#) [B](#) [C](#) [i](#)  
Hepatitis Hepatitis Hepatitis Info



---

## **Arden-Syntax-Server and MLMs at Universitätsklinikum Erlangen**

Dr. Ixchel Castellanos

Interdisziplinäre Operative Intensivmedizin, Anästhesiologische Klinik

and

Dipl.-Inform. Stefan Kraus

Lehrstuhl für Medizinische Informatik

---

|             |            |                   |              |      |              |
|-------------|------------|-------------------|--------------|------|--------------|
| BMI         | Kalium     | Natrium           | Calcium      | pH   | Thrombopenie |
| Schockindex | Leukozyten | MMI Interaktionen | Anionenlücke | GFR  | Tidalvolumen |
| Murrayscore | MELD-Score | PCT Allgemein     | PCT Herz     |      |              |
| Diagnosen   | MIbI Kneg  | MIbI DRG          | MIbI 7 Tage  | Demo |              |

Patient: \*\*\*\*\* | ISH-Aufnahmenummer: \*\*\*\*\* | Bettnummer: Bett 17 (5/1) | Orgeinheit: AN

#### MLM: ICM\_BMI

Patient \*\*\*\*\* hat einen **BMI von 30.1**.

Patient hat **Adipositas Grad I (E66.00)**.

**HINWEIS:** Diagnose E66.00 wurde noch nicht codiert!

Beenden

Drucken

|             |            |                   |              |      |              |
|-------------|------------|-------------------|--------------|------|--------------|
| BMI         | Kalium     | Natrium           | Calcium      | pH   | Thrombopenie |
| Schockindex | Leukozyten | MMI Interaktionen | Anionenlücke | GFR  | Tidalvolumen |
| Murrayscore | MELD-Score | PCT Allgemein     | PCT Herz     |      |              |
| Diagnosen   | MIbI Kneg  | MIbI DRG          | MIbI 7 Tage  | Demo |              |

Patient: \*\*\*\*\* | ISH-Aufnahmenummer: \*\*\*\*\* | Bettnummer: Bett 10 (4/2) | Orgeinheit: AN

#### MLM: ICM\_ANIONENLUECKE

Die Anionenlücke von \*\*\*\*\* beträgt **4** mmol/l.

#### Berechnungsgrundlage

Letzter Natriumwert: 153 (Alter: 3 Stunden 31 Minuten )  
Letzter Chloridwert: 127 (Alter: 3 Stunden 31 Minuten )  
Letzter HCO<sub>3</sub>-Wert: 22 (Alter: 3 Stunden 31 Minuten )

Verwendete Formel: Anionenlücke = Natrium - Chlorid - HCO<sub>3</sub>

Anionenlücke sollte bei verwendeter Formel zwischen 8 und 16 liegen.

Beenden

Drucken

## Monitoring

Glucose  
Kalium  
MONI

PCT-Studie

### Antwort von Medexter-Engine

**Aktuell ist keine Procalcitoninmessung erforderlich.**


Patient hat 33 Procalcitoninwerte.

Die letzte Procalcitoninmessung erfolgte am 05.07.2011 um 06:00 Uhr und ergab den Wert 0.08.

Die letzte Procalcitoninmessung liegt also 7 hours 28 minutes 34. seconds zurück.

Es wurden 13 vermeidbare Messungen gefunden: (4, 7, 9, 11, 13, 16, 18, 20, 22, 24, 26, 28, 31)

Das Einsparpotential liegt bei 182 Euro



Regression über alle Werte: -0.03

Regression über die letzten beiden Werte: 0

Trend: Veränderung pro Stunde: 0

| #   | Wert | Zeitstempel             |
|-----|------|-------------------------|
| 1.  | 3.22 | 29.05.2011 um 06:00 Uhr |
| 2.  | 1.86 | 30.05.2011 um 06:00 Uhr |
| 3.  | 0.97 | 31.05.2011 um 06:00 Uhr |
| 4.  | 0.55 | 01.06.2011 um 06:00 Uhr |
| 5.  | 0.36 | 02.06.2011 um 06:00 Uhr |
| 6.  | 0.17 | 04.06.2011 um 06:00 Uhr |
| 7.  | 0.42 | 05.06.2011 um 06:00 Uhr |
| 8.  | 0.33 | 06.06.2011 um 06:00 Uhr |
| 9.  | 0.08 | 07.06.2011 um 06:00 Uhr |
| 10. | 0.80 | 08.06.2011 um 06:00 Uhr |
| 11. | 0.30 | 09.06.2011 um 06:00 Uhr |
| 12. | 0.10 | 10.06.2011 um 06:00 Uhr |
| 13. | 0.10 | 11.06.2011 um 06:00 Uhr |
| 14. | 0.10 | 12.06.2011 um 06:00 Uhr |
| 15. | 0.10 | 13.06.2011 um 06:00 Uhr |
| 16. | 0.20 | 14.06.2011 um 06:00 Uhr |
| 17. | 0.20 | 15.06.2011 um 06:00 Uhr |
| 18. | 0.10 | 16.06.2011 um 06:00 Uhr |
| 19. | 0.20 | 17.06.2011 um 06:00 Uhr |
| 20. | 0.40 | 18.06.2011 um 06:00 Uhr |
| 21. | 0.30 | 19.06.2011 um 06:00 Uhr |
| 22. | 0.30 | 20.06.2011 um 06:00 Uhr |
| 23. | 0.40 | 21.06.2011 um 06:00 Uhr |
| 24. | 0.30 | 22.06.2011 um 06:00 Uhr |
| 25. | 0.20 | 23.06.2011 um 06:00 Uhr |
| 26. | 0.10 | 24.06.2011 um 06:00 Uhr |
| 27. | 0.10 | 25.06.2011 um 06:00 Uhr |
| 28. | 0.10 | 26.06.2011 um 06:00 Uhr |
| 29. | 0.10 | 27.06.2011 um 06:00 Uhr |
| 30. | 0.10 | 28.06.2011 um 06:00 Uhr |
| 31. | 0.10 | 29.06.2011 um 06:00 Uhr |
| 32. | 0.10 | 30.06.2011 um 06:00 Uhr |
| 33. | 0.08 | 01.07.2011 um 06:00 Uhr |

## Use Case: Hypoglycemia

- Hypoglycemia may seriously harm
- If patient is unconscious, it is difficult to notice
- The PDMS should actively notify the physician:

If glucose is less than 50mg/dl,  
then send an SMS message to the physician.

## Use Case: Hypoglycemia

### DATA:

LET glucose BE READ {...glucose...};

LET physician\_DECT BE DESTINATION {sms:26789};

### LOGIC:

IF LATEST glucose IS LESS THAN 50 THEN

CONCLUDE true;

ENDIF;




**CONCLUDE TRUE**  
→ Do something

### ACTION:

WRITE „Warning...” AT physician\_DECT;

## Use Case: Hypoglycemia



Event monitors are

„tireless observers,  
constantly monitoring  
clinical events“

(George Hripscak)

by Stefan Kraus

---

## Implementation

### three-step approach

- awareness by clinicians, technicians, and administration; willingness to invest in evidence-based care, quality measures, legal confidence
  - form a CDS governance committee (clinicians and technicians, backed by administration)
  - demand and install specific CDS solutions and/or a general CDS tool for enterprise-wide knowledge authoring
-



---


## **Clinical perspectives**

---

---

## Regulatory affairs—I

- stand alone software
  - **Meddev 2.1/6:** Guidelines on the qualification and classification of stand alone software used in healthcare within the regulatory framework of medical devices (MDs) (January 2012)



---

## Regulatory affairs—II

- MDD 93/42/EEC
  - amended by Directive 2007/47/EG (21 September 2007)

### Article 1, Paragraph 2a (art. 1.2a of MDD):

Medical device (MD) means any instrument, apparatus, appliance, **software**, material or other article, whether used alone or in combination, ... intended by the manufacturer to be used for human beings for the purpose of:


- diagnosis, prevention, monitoring, treatment, or alleviation of disease
- ...




medical device

---

## Medical device certification



# Clinical medicine



---

# Clinical medicine: high complexity

- **sources of medical knowledge**
  - definitional
  - causal
  - statistical
  - heuristic
- **layers of medical knowledge**
  - observational and measurement level
  - interpretation, abstraction, aggregation, summation
  - pathophysiological states
  - diseases/diagnoses, therapies, prognoses, management decisions
- **imprecision, uncertainty, and incompleteness**
  - imprecision (=fuzziness) of medical concepts
    - \* due to the unsharpness of boundaries of linguistic concepts
  - uncertainty of medical conclusions
    - \* due to the uncertainty of the occurrence and co-occurrence of imprecise medical concepts
  - incompleteness of medical data and medical theory
    - \* due to only partially known data and partially known explanations for medical phenomena
- **“gigantic” amount of medical data and medical knowledge**
  - patient history, physical examination, laboratory test results, clinical findings
  - symptom-disease relationships, disease-therapy relationships, ...
  - terminologies, ontologies: SNOMED CT, LOINC, UMLS, ...



specialization, teamwork, quality management, computer support


---

---

## **Clinical medicine: hidden treasures**

- holistic diagnosis
    - knowledge and intuition, symptomatic vs. causal therapy, medication history
    - patient's non-formalizable/non-digitizable data
  - probable vs. possible diagnoses
    - interpretation of findings, suspected diagnosis, clinical diagnosis, pathological diagnosis
    - pattern matching, most probable diagnosis, sensitivity, specificity, prevalence
  - terminology in context
    - not every diagnostic term is a diagnosis
    - psychology: cold, flu, malaria, ...
-

from 2013-05-01 to 2013-05-15 show clinic hide department diagram fixed column width



## Moni-ICU: surveillance of healthcare-associated infections

| department / patient | Pat. 696043                         | BSI-A (primary sepsis)  |
|----------------------|-------------------------------------|---|
| Stat. 10865          | 2013-06-02 not at ICU               | pos. blood culture (t-7d - t)                                 |
| Stat. 10896          | 2013-06-01 not at ICU               |   |
| Stat. 10897          | 2013-05-31 not at ICU               | pos. blood culture (t-7d - t)                                 |
| Stat. 10898          | 2013-05-30 not at ICU               | 2013B008329, 2013-05-23 10:00: Blut (zentral): Candida krusei |
| Stat. 11051          | 2013-05-29 not at ICU               |   |
| Stat. 11053          | 2013-05-28 (Stat. 39690)            |   |
| Stat. 11082          | 2013-05-27 (Stat. 39690)            |   |
| Stat. 11083          | 2013-05-26 (Stat. 39690)            |   |
| Stat. 39690          | 2013-05-25 (Stat. 39690)            |   |
| Pat. 1464096         | 2013-05-24 (Stat. 39690)            |   |
| Pat. 1464121         | BSI-A (primary sepsis)              | 100 %DoC  |
| Pat. 1464127         | PN3 (bact. indication of pneumonia) | 100 %DoC  |
| Pat. 696049          | inflamm. symptoms in UTI            | 100 %DoC  |
| Pat. 696052          | inflamm. symptoms in sepsis         | 100 %DoC  |
| Pat. 1464108         | fever                               | 100 %DoC  |
| Pat. 1464117         | hypotension                         | 80 %DoC   |
| Pat. 696045          | high CRP                            | 100 %DoC  |
| Pat. 1464102         | leukozytosis                        | 100 %DoC  |
| Pat. 1464110         | blood pressure falling              | 100 %DoC  |
| Pat. 1464119         | shock                               | 100 %DoC  |
| Pat. 1464106         | high body temperature               | 100 %DoC  |
| Pat. 1464100         | max. body temperature               | 39 °C   |
| Pat. 1464125         | fraction of leukocytes              | 14.91 G/L   |
| Pat. 1464115         | systemic antibiotics                | yes   |
| Pat. 696042          | pos. blood culture                  | 100 %DoC  |
| Pat. 1464104         | 2013-05-23 (Stat. 39690)            |   |
| Pat. 1464125         | BSI-A (primary sepsis)              | 100 %DoC  |
| Pat. 1464098         | PN3 (bact. indication of pneumonia) | 100 %DoC  |
| Pat. 1464115         | inflamm. symptoms in UTI            | 100 %DoC  |
| Pat. 696042          | inflamm. symptoms in sepsis         | 100 %DoC  |



| department / patient |  |
|----------------------|--|
| Stat. 10865          |  |
| Stat. 10896          |  |
| Stat. 10897          |  |
| Stat. 10898          |  |
| Stat. 11051          |  |
| Stat. 11053          |  |
| Stat. 11082          |  |
| Stat. 11083          |  |
| Stat. 39690          |  |
| Stat. 62354          |  |
| Stat. 62621          |  |

|      |         |
|------|---------|
| Pat. | 696343  |
| Pat. | 696628  |
| Pat. | 1464405 |
| Pat. | 1464409 |
| Pat. | 1464384 |
| Pat. | 696414  |
| Pat. | 1464439 |
| Pat. | 1464444 |
| Pat. | 696434  |
| Pat. | 1464393 |
| Pat. | 1464380 |
| Pat. | 1464470 |
| Pat. | 696334  |
| Pat. | 1464428 |
| Pat. | 1464423 |
| Pat. | 696318  |
| Pat. | 696328  |
| Pat. | 1464402 |
| Pat. | 696596  |
| Pat. | 696603  |

|             |  |
|-------------|--|
| Stat. 11408 |  |
| Stat. 30488 |  |

| Pat. 1464393                                     |          |
|--|----------|
| 2013-05-29 (Stat. 30488)                         |          |
| 2013-05-28 (Stat. 30488)                         |          |
| 2013-05-27 (Stat. 30488)                         |          |
| 2013-05-26 (Stat. 30488)                         |          |
| 2013-05-25 (Stat. 30488)                         |          |
| 2013-05-24 (Stat. 30488)                         |          |
| 2013-05-23 (Stat. 30488)                         |          |
| 2013-05-22 (Stat. 30488)                         |          |
| 2013-05-21 (Stat. 30488)                         |          |
| 2013-05-20 (Stat. 30488)                         |          |
| 2013-05-19 (Stat. 30488)                         |          |
| 2013-05-18 (Stat. 30488)                         |          |
| 2013-05-17 (Stat. 30488)                         |          |
| BSI-3 (KISS)                                     | 100 %DoC |
| BSI-3 (alert)                                    | 100 %DoC |
| 2 clin. signs of sepsis (KISS)                   | 100 %DoC |
| 2 clin. signs of sepsis (alert)                  | 100 %DoC |
| 2 lab. and clin. signs of sepsis (KISS)          | 100 %DoC |
| 2 lab. and clin. signs of sepsis (alert)         | 100 %DoC |
| imp.: no pathogen in specimen other than bloo... | yes      |
| imp.: no blood culture                           | yes      |
| imp.: not ventilated                             | yes      |
| imp.: not ventilated (KISS)                      | yes      |
| imp.: antiinfective                              | yes      |
| 2013-05-16 (Stat. 30488)                         |          |
| 2013-05-15 (Stat. 30488)                         |          |
| 2013-05-14 (Stat. 30488)                         |          |
| 2013-05-13 (Stat. 30488)                         |          |
| 2013-05-12 (Stat. 62621, Stat. 30488)            |          |
| 2013-05-11 (Stat. 62621)                         |          |
| 2013-05-10 (Stat. 62621)                         |          |
| 2013-05-09 (Stat. 62621)                         |          |
| 2013-05-08 (Stat. 62621)                         |          |
| 2013-05-07 (Stat. 62621)                         |          |
| 2013-05-06 (Stat. 62621)                         |          |
| 2013-05-05 (Stat. 62621)                         |          |
| 2013-05-04 (Stat. 62621)                         |          |
| 2013-05-03 (Stat. 62621)                         |          |
| 2013-05-02 (Stat. 62621)                         |          |

| BSI-3 (KISS)                                     |          |
|--|----------|
| AND  | 100 %DoC |
| imp.: no blood culture                           | yes      |
| imp.: no pathogen in specimen other than bloo... | yes      |
| antiinfectives for 5 days                        | 100 %DoC |
| 2 lab. and clin. signs of sepsis (KISS)          | 100 %DoC |

| 2 lab. and clin. signs of sepsis (KISS) |          |
|---|----------|
| AT LEAST 2 OF                           | 100 %DoC |
| pathol. heart rate (definition)         | 100 %DoC |
| pathol. Breathing (autom.)              | 100 %DoC |



| pathol. Breathing (autom.)      |          |
|---------------------------------|----------|
| OR                              | 100 %DoC |
| tachypnea events increasing     | 100 %DoC |
| increasing breath rate (80%DoC) | 54 %DoC  |

| tachypnea events increasing               |         |
|---|---------|
| tachypnoea event (abs.) (t-1d)            | 1.46 /h |
| tachypnoea event (abs.) (Intervall): Max. | 3.5 /h  |

**Moni-NICU:**  
(surveillance of and) alerts for  
healthcare-associated  
infections

# Differential diagnosis of rheumatic diseases



# Clinically-oriented interpretation of hepatitis serology test results

Carrier 11:50 AM 100%

## Hepaxpert/Interpretation

Knowledge-based interpretation of hepatitis A, B, and C serology

### Input of test results

#### Hepatitis A serology

anti-HAV ☒ positive ☐ negative ☐ borderline ☐ not tested  
 IgM anti-HAV ☐ positive ☒ negative ☐ borderline ☐ not tested  
 HAV-RNA ☐ positive ☒ negative ☐ borderline ☐ not tested

#### Hepatitis B serology

HBsAg ☐ positive ☒ negative ☐ borderline ☐ not tested  
 anti-HBs ☐ positive ☒ negative ☐ borderline ☐ not tested  
 anti-HBc ☒ positive ☐ negative ☐ borderline ☐ not tested  
 IgM anti-HBc ☒ positive ☐ negative ☐ borderline ☐ not tested  
 HBeAg ☐ positive ☒ negative ☐ borderline ☐ not tested  
 anti-HBe ☐ positive ☒ negative ☐ borderline ☐ not tested  
 anti-HBs titre  U/I

#### Hepatitis C serology

anti-HCV ☒ positive ☐ negative ☐ borderline ☐ not tested  
 HCV-RNA ☐ positive ☐ negative ☐ borderline ☒ not tested

[Submit](#)

© 2007–2011 Medexel. All rights reserved.

Carrier 11:45 AM

## Hepaxpert/Interpretation

Knowledge-based interpretation of hepatitis A, B, and C serology

### Interpretation

#### Hepatitis A serology

**anti-HAV** **positive** **IgM anti-HAV** **negative** **HAV-RNA** **negative**  
 Positive results for total anti-HAV antibodies in combination with negative results for IgM anti-HAV antibodies indicate immunity to the hepatitis virus A and exclude the possibility of a recent hepatitis A. This immunity may either have been acquired naturally through an earlier infection or it may have been induced by active vaccination or passively acquired immunization.

#### Hepatitis B serology

**HBsAg** **negative** **anti-HBs** **negative** **anti-HBc** **positive** **IgM anti-HBc** **positive** **HBeAg** **negative** **anti-HBe** **negative** **anti-HBs titre** **not tested**  
 This constellation of findings (positive IgM anti-HBc antibodies with negative HBs- and HBe-antigen and negative anti-HBs and anti-HBe antibodies) occurs in the course of acute hepatitis B and is characteristic of the seroconversion both of HBs-antigen to anti-HBs and of HBe-antigen to anti-HBe antibodies. This stage may be regarded as a favorable prognostic sign with a view to a non-chronic course of the disease. Blood and secretions (saliva, sperm, breast milk) of the patient are to be considered infectious.

#### Hepatitis C serology

**anti-HCV** **positive** **HCV-RNA** **not tested**  
 There is a recent or chronic persisting or an earlier hepatitis C virus infection. An additional test for HCV-RNA adds further information. Blood of such patients may be considered as infectious with regard to hepatitis C.

#### Important Notice

The attending physician alone is responsible for the patient's diagnosis and therapy. Therefore, contact a doctor at all times. Only the doctor will be able to align the Hepaxpert interpretation with the full clinical picture of the patient.

[Reset](#)

© 2007–2011 Medexel. All rights reserved.

Carrier 11:47 AM

## Hepatitis B Serology

[Reset](#) [Submit](#)

### Parameters

**HBsAg** **negative**  
**anti-HBs** **negative**  
**anti-HBc** **positive**  
**IgM anti-HBc** **positive**  
**HBeAg** **negative**  
**anti-HBe** **negative**  
**anti-HBs titre** **not tested**

[A](#) [B](#) [C](#) [i](#)  
 Hepatitis Hepatitis Hepatitis Info

Carrier 11:48 AM

## Hepatitis B Serology

[Reset](#) [Submit](#)

### anti-HBs titre


**not tested**

### Results

This constellation of findings (positive IgM anti-HBc antibodies with negative HBs- and HBe-antigen and negative anti-HBs and anti-HBe antibodies) occurs in the course of acute hepatitis B and is characteristic of the seroconversion both of HBs-antigen to anti-HBs and of HBe-antigen to anti-HBe antibodies. This stage may be regarded as a favorable prognostic sign with a view to a non-chronic course of the disease. Blood and secretions (saliva, sperm, breast milk) of the patient are to be considered infectious.


[A](#) [B](#) [C](#) [i](#)  
 Hepatitis Hepatitis Hepatitis Info

# Arden Syntax software: generic technology platform for clinical decision support



---

## Clinical reality and software artefacts: a sociotechnical, interdependent system



certification of both clinicians and software  $\Rightarrow$  best care through best quality

---